Bony toxicity    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
34Neurofibromatosis1

34. Neurofibromatosis    [ 120 clinical trials,   182 drugs,   (DrugBank: 72 drugs),   84 drug target genes,   194 drug target pathways]
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 120 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00727233
(ClinicalTrials.gov)
July 8, 200831/7/2008Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform NeurofibromasPhase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform NeurofibromasNeurofibromatosis Type I;Plexiform NeurofibromaDrug: Nexavar (BAY 43-9006) (Sorafenib);Drug: Toxicity, Pharmacokinetics;Drug: Pharmacodynamics;Drug: Radiographic Evaluation;Drug: QOL assessment, Neuropsychological;Drug: Bony ToxicityNational Cancer Institute (NCI)NULLCompleted3 Years18 YearsAll9Phase 1United States